Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC10004 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 20 mg Apremilast daily | EXPERIMENTAL | 20 mg of CC-10004 daily |
| 20mg Apremilast twice daily | EXPERIMENTAL | CC-10004 twice daily |
| Placebo | PLACEBO_COMPARATOR | Placebo arm |
| Administration of CC10004 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-10004 | DRUG | 20 mg CC-10004 taken 1 time per day for 12 weeks |
| Placebo | DRUG | matching placebo taken either 1 or 2 times per day for 12 weeks |
| CC10004 | DRUG | 2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted |
Inclusion Criteria: * Must understand and voluntarily sign and informed consent form * Must be in good health as judged by the investigator * Must be able to adhere to the study visit schedule and other protocol requirements * Must have greater than or equal to a 6 month history of moderate-to-seve...
CC10004 is an investigational small molecule being developed for the treatment of psoriasis, specifically severe plaque type psoriasis and moderate to severe plaque type psoriasis. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
CC10004 is being developed by Amgen Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with psoriasis.
CC10004 is in Phase 2 clinical development. Two Phase 2 trials have been completed, both involving patients with plaque type psoriasis. The drug is investigational and has not been approved for any use, meaning it is still undergoing clinical evaluation.
CC10004 has been studied in two completed Phase 2 trials. NCT00604682 was an open-label, single-arm pilot study in 19 patients with severe plaque type psoriasis in the United States. NCT00606450 was a double-blind, randomized, placebo-controlled trial in 260 patients with moderate to severe plaque type psoriasis in Canada, Czechia, and Germany.
CC10004 is also known as apremilast, a small molecule being developed by Amgen Inc. for the treatment of psoriasis. The drug has been evaluated in Phase 2 clinical trials, including a placebo-controlled study, but it remains investigational and is not yet approved.